The University of Southampton
University of Southampton Institutional Repository

Use of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptor-positive breast cancer: a meta-analysis of individual patient data from randomised adjuvant trials

Cuzick, J., Ambroisine, L., Davidson, N., Jakesz, R., Kaufmann, M., Regan, M. and Sainsbury, R. LHRH-agonists in Early Breast Cancer Overview group (2007) Use of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptor-positive breast cancer: a meta-analysis of individual patient data from randomised adjuvant trials The Lancet, 369, (9574), pp. 1711-1723. (doi:10.1016/S0140-6736(07)60778-8).

Record type: Article

Abstract

Background: Several trials have been done to assess treatment of premenopausal breast cancer with luteinising-hormone-releasing hormone (LHRH) agonists, but results have been inconclusive, especially for patients with hormone-receptor-positive cancer.
Methods: We collected individual patients' data from published trials and did analyses focused on women with tumours positive for oestrogen receptor, progesterone receptor, or both. The main endpoints were recurrence and death after recurrence.
Findings: We obtained data for 11 906 premenopausal women with early breast cancer randomised in 16 trials. When used as the only systemic adjuvant treatment, LHRH agonists did not significantly reduce recurrence (28·4% relative reduction, 95% CI consistent with 50·5% reduction to 3·5% increase, p=0·08) or death after recurrence (17·8%, 52·8% reduction to 42·9% increase, p=0·49) in hormone-receptor-positive cancers. Addition of LHRH agonists to tamoxifen, chemotherapy, or both reduced recurrence by 12·7% (2·4–21·9, p=0·02); and death after recurrence by 15·1% (1·8–26·7, p=0·03). LHRH agonists showed similar efficacy to chemotherapy (recurrence 3·9% increase, 7·7% reduction to 17·0% increase; death after recurrence 6·7% reduction, 20·7% reduction to 9·6% increase; both not significant). No trials had assessed an LHRH agonist versus chemotherapy with tamoxifen in both arms. LHRH agonists were ineffective in hormone-receptor-negative tumours.
Interpretation: LHRH agonists provide an additional class of agents for treatment of premenopausal women with hormone-receptor-positive breast cancer. Optimum duration of use is unknown.

Full text not available from this repository.

More information

Published date: 2007
Organisations: Cancer Sciences

Identifiers

Local EPrints ID: 49323
URI: http://eprints.soton.ac.uk/id/eprint/49323
ISSN: 0140-6736
PURE UUID: 8ba90fed-e236-452a-8dc7-81027d1a7988

Catalogue record

Date deposited: 30 Oct 2007
Last modified: 17 Jul 2017 14:56

Export record

Altmetrics

Contributors

Author: J. Cuzick
Author: L. Ambroisine
Author: N. Davidson
Author: R. Jakesz
Author: M. Kaufmann
Author: M. Regan
Author: R. Sainsbury

University divisions

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×